Eyebright Begin Period Cash Flow from 2010 to 2024

688050 Stock   89.09  0.66  0.74%   
Eyebright Medical's Begin Period Cash Flow is increasing over the years with slightly volatile fluctuation. Begin Period Cash Flow is expected to dwindle to about 234.5 M. Begin Period Cash Flow is the amount of cash Eyebright Medical Technology has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2019-03-31
Previous Quarter
536.7 M
Current Value
367.9 M
Quarterly Volatility
141.7 M
 
Covid
Check Eyebright Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyebright Medical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 70.9 M, Interest Expense of 10.3 M or Selling General Administrative of 226.9 M, as well as many indicators such as . Eyebright financial statements analysis is a perfect complement when working with Eyebright Medical Valuation or Volatility modules.
  
This module can also supplement various Eyebright Medical Technical models . Check out the analysis of Eyebright Medical Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Eyebright Stock

Eyebright Medical financial ratios help investors to determine whether Eyebright Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eyebright with respect to the benefits of owning Eyebright Medical security.